Design, Conduct, and Analyses of Breast International Group (BIG) 1-98: A Randomized, Double-Blind, Phase-Iii Study Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor-Positive, Early Breast Cancer

Clinical Trials - United Kingdom
doi 10.1177/1740774509105380
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Cognitive Function in Postmenopausal Breast Cancer Patients One Year After Completing Adjuvant Endocrine Therapy With Letrozole and/or Tamoxifen in the BIG 1-98 Trial

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer

Breast Care
SurgeryOncology
2008English

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Low P27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy

Clinical Cancer Research
Cancer ResearchOncology
2009English

Adjuvant Endocrine Monotherapy for Postmenopausal Early Breast Cancer Patients With Hormone-Receptor Positive: A Systemic Review and Network Meta-Analysis

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2017English

Efficacy of First-Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women With Advanced Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2004English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

MiR-4653-3p and Its Target Gene FRS2 Are Prognostic Biomarkers for Hormone Receptor Positive Breast Cancer Patients Receiving Tamoxifen as Adjuvant Endocrine Therapy

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy